February 24th- Defining Cure in Multiple Myeloma: A Community Consensus Moment

CME Congresses .

February 24th- Defining Cure in Multiple Myeloma: A Community Consensus Moment

February 23rd- Prof. Roni Shouval- Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

CME Congresses .

February 23rd- Prof. Roni Shouval- Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

February 22nd- Beyond the webinar: Chronic GVHD in 2026: From Frustration to Structured Progress

CME Congresses .

February 22nd- Beyond the webinar: Chronic GVHD in 2026: From Frustration to Structured Progress

February 16th- Dr. Marie Robin- Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability

CME Congresses .

February 16th- Dr. Marie Robin- Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability

February 15th- CML in 2026: From Disease Control to Functional Cure

CME Congresses .

February 15th- CML in 2026: From Disease Control to Functional Cure

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

CME Congresses .

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

February 4th- A New Step Forward in Chronic GVHD Care

CME Congresses .

February 4th- A New Step Forward in Chronic GVHD Care

February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

CME Congresses .

February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial

CME Congresses .

February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial

February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma

CME Congresses .

February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma